R Tony Tripeny Acquires 900 Shares of Mesa Laboratories (NASDAQ:MLAB) Stock

Key Points

• Director R. Tony Tripeny bought 900 Mesa Laboratories shares at an average price of $113.69, investing $102,321 and increasing his direct ownership by 16.67% to 6,298 shares.
• Mesa Laboratories reported quarterly revenue of $60.14 million and earnings of $2.68 per share, while its stock traded up 2.0% to $108.19.
• The company declared a quarterly dividend of $0.16 per share, or $0.64 annualized, representing a 0.6% yield; analysts maintain a consensus “Hold” rating with a $110 target price.

Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) Director R Tony Tripeny bought 900 shares of Mesa Laboratories stock in a transaction that occurred on Thursday, August 13th. The shares were acquired at an average price of $113.69 per share, for a total transaction of $102,321.00. Following the completion of the transaction, the director directly owned 6,298 shares of the company's stock, valued at $716,019.62. This trade represents a 16.67% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mesa Laboratories Trading Up 2.0%

MLAB traded up $2.15 during midday trading on Monday, hitting $108.19. The company's stock had a trading volume of 77,359 shares, compared to its average volume of 147,914. Mesa Laboratories, Inc. has a 52-week low of $58.83 and a 52-week high of $115.52. The firm has a 50-day moving average price of $100.64 and a two-hundred day moving average price of $96.07. The company has a current ratio of 1.79, a quick ratio of 1.32 and a debt-to-equity ratio of 0.73. The firm has a market cap of $605.40 million, a P/E ratio of 128.81 and a beta of 0.92.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share for the quarter. Mesa Laboratories had a net margin of 1.92% and a return on equity of 22.72%. The business had revenue of $60.14 million for the quarter.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Monday, August 31st will be given a dividend of $0.16 per share. The ex-dividend date of this dividend is Monday, August 31st. This represents a $0.64 annualized dividend and a yield of 0.6%. Mesa Laboratories's dividend payout ratio is 76.19%.

Institutional Trading of Mesa Laboratories

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Boston Partners raised its holdings in Mesa Laboratories by 86.6% in the fourth quarter. Boston Partners now owns 213,376 shares of the medical instruments supplier's stock valued at $16,752,000 after buying an additional 99,019 shares during the period. Ranger Investment Management L.P. purchased a new stake in Mesa Laboratories during the second quarter worth approximately $17,321,000. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in Mesa Laboratories during the second quarter worth approximately $15,507,000. Royce & Associates LP increased its position in shares of Mesa Laboratories by 3.2% in the fourth quarter. Royce & Associates LP now owns 153,352 shares of the medical instruments supplier's stock worth $12,038,000 after acquiring an additional 4,794 shares in the last quarter. Finally, Kennedy Capital Management LLC raised its stake in shares of Mesa Laboratories by 19.0% in the 4th quarter. Kennedy Capital Management LLC now owns 144,606 shares of the medical instruments supplier's stock valued at $11,352,000 after acquiring an additional 23,060 shares during the period. Institutional investors and hedge funds own 90.60% of the company's stock.

Analyst Upgrades and Downgrades

MLAB has been the topic of a number of research analyst reports. Weiss Ratings upgraded shares of Mesa Laboratories from a "sell (d)" rating to a "hold (c-)" rating in a report on Tuesday, August 11th. Wall Street Zen lowered Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Finally, Wells Fargo & Company lifted their target price on Mesa Laboratories from $94.00 to $110.00 and gave the company an "equal weight" rating in a report on Friday. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $110.00.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc NASDAQ: MLAB is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source